XLAMIDIOZ  KASALLIGIDA IMMUN JAVOB VA ZAMONAVIY DIAGNOSTIKA USULLAR

Jalg'ashova Durdona Murod qizi; Xolmurodov Inoyatullo Ismatulloyevich

Authors

Jalg'ashova Durdona Murod qizi Termiz iqtisodiyot va servis universiteti Tibbiyot fakulteti Davolash ishi yoʻnalishi 2-kurs 24-09 guruh talaba
Xolmurodov Inoyatullo Ismatulloyevich Termiz iqtisodiyot va servis universiteti Tibbiyot fakulteti Davolash ishi yoʻnalishi 2-kurs 24-09 guruh talabal

Keywords:

Chlamydia trachomatis, urogenital xlamidioz, Chlamydia trachomatis infeksiyasi, immun javob, innate immunitet, adaptive immunitet, immun evasion, immun qochish mexanizmlari, Type III secretion system, T3SS effektorlari, TepP, TarP, CpoS, IFN-γ, IL-1, TNF-α, Th1 limfotsitlari, CD4+ T-hujayralari, HSP60, immunopatologiya, surunkali yallig‘lanish, autoimmun reaksiyalar, bepushtlik asoratlari, tos yallig‘lanishi, NAAT, Nucleic Acid Amplification Tests, PZR, PCR, real vaqtda PCR, point-of-care testlar, POC diagnostika, lateral flow testlar, molekulyar diagnostika, zamonaviy diagnostika usullari, skrining, vaktsina ishlab chiqish, immun evasion strategiyalari, hujayra ichi parazitizmi, apoptoz inhibisyasi, MHC ekspressiyasi pasayishi, Th1/Th2 muvozanati, shilliq qavat immuniteti, mahalliy immun javob, surunkali infeksiya patogenezi

Abstract

Xlamidioz — Chlamydia trachomatis bakteriyasi qo‘zg‘atadigan eng keng tarqalgan jinsiy yo‘l bilan yuqadigan infeksiya bo‘lib, ko‘pincha asemptomatik kechadi va ayollarda bepushtlik, ektopik homiladorlik, surunkali tos yallig‘lanishi kabi jiddiy asoratlarga olib kelishi mumkin. Ushbu maqola Chlamydia trachomatis infeksiyasida organizmning immun javob mexanizmlari va zamonaviy diagnostika yondashuvlarini batafsil yoritadi.

References

1.White JA, Dukers-Muijrers NHTM, Hoebe CJPA, et al. 2025 European guideline on the management of Chlamydia trachomatis infections. International Journal of STD & AIDS. 2025;36(6):434-449. doi:10.1177/09564624251323678. (Davolash, diagnostika va skrining bo‘yicha asosiy qo‘llanma; doksitsiklinni birinchi tanlov sifatida tavsiya etadi.)

2.Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections Treatment Guidelines, 2021 (2021 yilgi versiya, 2025–2026 yillarda yangilanishlarsiz asosiy manba sifatida ishlatilgan). Chlamydial Infections bo‘limi. https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm (Doksitsiklin va azitromitsin taqqoslovi, sheriklar davolanishi.)

3.World Health Organization (WHO). WHO guidelines for the treatment of Chlamydia trachomatis. 2016 (yangilangan tavsiyalar 2024–2025 yillarda e’lon qilingan qo‘shimchalar bilan). https://www.who.int/publications/i/item/who-guidelines-for-the-treatment-of-chlamydia-trachomatis (Umumjahon davolash va profilaktika.)

4.Hafner LM. Pathogenesis of fallopian tube damage caused by Chlamydia trachomatis infections. Contraception. 2015;92(5):421-429. (Immunopatologiya va HSP60 roli bo‘yicha

klassik ko‘rib chiqish.)

5.Linhares IM, Witkin SS. Immunopathogenic consequences of Chlamydia trachomatis 60 kDa heat shock protein expression in the female reproductive tract. Gynecologic and Obstetric Investigation. 2010;70(4):259-265. doi:10.1159/000320290. (HSP60 va autoimmun mexanizmlar batafsil.)

6.Wang X, et al. Insights into innate immune cell evasion by Chlamydia trachomatis. Frontiers in Immunology. 2024;15:1289644. doi:10.3389/fimmu.2024.1289644. (Immun evasion mexanizmlari, T3SS effektorlari haqida yangi ma’lumotlar.)

7.Filardo S, et al. Anti-Chlamydia trachomatis Host Defence Arsenal Within the Cervicovaginal Environment. International Journal of Molecular Sciences. 2026;27(2):1115. (Mahalliy immunitet va evasion strategiyalari.)

8.McCullough A, et al. Pathogenicity and virulence of Chlamydia trachomatis: Insights into host interactions, immune evasion, and intracellular survival. Virulence. 2025;16(1):2503423. doi:10.1080/21505594.2025.2503423. (Patogenez va aberrant body shakli.)

9.Geisler WM, et al. Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection. New England Journal of Medicine. 2015;373(26):2512-2521. (Klassik taqqoslash tadqiqoti, keyingi meta-tahlillar uchun asos.)

10.Kong FYS, et al. Azithromycin Versus Doxycycline for the Treatment of Genital Chlamydia Infection: A Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases. 2014;59(2):193-205. (Meta-tahlil, doksitsiklin afzalligi.)

11.Khosropour CM, et al. Trends in Chlamydia Prescribing Practices After Changes to National Treatment Guidelines in the United States, 2016-2023. Sexually Transmitted Diseases. 2026 (doksitsiklin qo‘llanilishidagi o‘sish haqida.)

12.Van Caesbroeck A, et al. Unveiling Chlamydia trachomatis immunity in urogenital secretions: A systematic review. iScience. 2025. (Mahalliy immun javob va biomarkerlar.)

13.Current Medical Diagnosis & Treatment 2025. Chapter: Chlamydia Trachomatis Infections. AccessMedicine, McGraw Hill. (Umumiy klinik ko‘rib chiqish.)

14.Guideline for the diagnosis and treatment of Chlamydia trachomatis urogenital infection in China (2024). Chinese Journal of Dermatology. 2024. (Xitoy qo‘llanmasi, sharqiy mintaqa uchun qiyosiy ma’lumot.)